Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Hi mate, i suggest you speak to the company, i won't post the conversation i have had with the company as i haven't asked permission but i am happy holding and looking forward to any update. GL
'The biomarker market is estimated to be $6 billion for the protein biomarker market and $21 billion for the total biomarker market by 2013. The following areas: drug discovery, clinical development, molecular diagnostics and personalized medicine account for 48% of the total market. The market is expected to grow by approximately 17% per year. Concerning seasonal fluctuations; the demand for biomarker services increases in the second-half in comparison to the first-half.'
Buy on PLUS, 1,195,530 @ .07p. Good to see. 1 or 2 more and we should have a tick up here, moves on little volume. GLA
I was in June '09 lol sp was .88p then! Hey ho.
Wish i didn't sell these a couple of years ago, well done all holders! Mental riser today...
Great RNS this morning, placing above current sp. Bodes very well. GLA
We appear to be moving back up again today. News on Turkey should be soon! Large buyer out there still also, would have thought another holdings RNS is imminant as well. GLA
I asked a few, send me an email, i think you have my e-mail address!? I will tell what I know. ATB mate.
In the last 2 days I have had a reply to a couple of emails sent, I will not disclose the contents as I didn't ask permission but i'm very happy with the answers, I would suggest anyone else who wants info does the same. I spoke to Leif Hamø the CFO. A very confident hold for me. GLA
Seen as the grant was done at .1p which is over 25% higher than the current sp (like the recent placing) i believe it's positive.
NextGen Group plc announces that on 6 September 2010 options were granted over 107,592,757 ordinary shares of 0.1p each to an employee of the Group. These options are subject to the Rules of the Group's share option plan. http://investegate.co.uk/Article.aspx?id=201009071113292757S
When is a good question... I think the company is the market leader in as much as their technology and capabilities. We have to remember that their full time commitment to the US is still in it's infancy really. The recent tie up with Takeda was a great achievement for the company and adds to further relationships we already have with other companies like Thermofisher. I think this company is in a very vulnerable position for a T/O with it's current market cap but as said here before not sure how a T/O would work with the majority shareholder owning c85% of the company. It would have to be a very good offer for them to make money on their investment. The most likely outcome IMO is that we will collaborate with another pharmaceutical company to strengthen them in our key areas. With this is mind i still have faith i will be rewarded for holding. Any good news will see a dramatic rise in sp as their are very few shares in circulation (sounds silly with so many in issue but most are tightly held). Hopefully we will see the start of an overdue turnaround very soon. ATB & GL
As long as you are seeing rewards from it, that's the main thing ;) I have to say i am tempted to pick up just a few more at these levels. Any good news will have a dramatic affect. Just a waiting game. ATB
Hi mate, long time no speak! Where you been hiding? lol Still holding out faith in here as i believe any good news will see this start an overdue turnaround. ATB
From the current trading and outlook: In 2010 NextGen has completed multiple biomarker projects and has further projects in the pipeline. The company has begun to introduce its own 'assay panels' to the market place in therapeutically relevant areas. A key element to gaining market presence and overcoming the technology adoption hurdles is the release and marketing of our own 'assay panels'. It is clear already that the CSF assay panel is enabling the company to gain market penetration although it is still early stages. It is envisaged that the Plasma panel, targeted at the Oncology market will also greatly enhance our presence in and relevance to the market. The key next stage will be to deliver discovery and qualification (testing) projects to customers with own 'assay panels' and to publish/present that work to clearly demonstrate the value proposition. Delivery of own 'assay panels' and demonstration through testing projects will enable the company to present a strong argument to the pharmaceutical and biotech market regarding the 'niche' role the company's technology can play in their pre-clinical and clinical development programs and also in their drive to develop companion diagnostics for their drug products. NextGen's ability to narrow the funnel from large numbers of potential biomarkers to small, manageable number of qualified biomarkers in a 6-month time window presents a real competitive advantage. This capability also presents NextGen with the opportunity to identify, play a role in and invest in projects that will develop and deliver companion and clinical diagnostics, thus opening the door to IP access and to revenues from diagnostic and personalized medicine products.
Highlights · New business plan written to redefine the product options and align these with market access · Core focus remains on biomarker discovery, assay development and biomarker qualification · Simplification of product mix to focus resource on custom biomarker projects and on developing therapeutically relevant 'assay panels' for biomarker discovery and qualification · New product lines identified for development; Plasma and Cerebrospinal Fluid assay panels for biomarker discovery and qualification · Cerebrospinal Fluid assay panel (19 protein) launched in May 2010 targeting the Central Nervous System market segment and in particular Alzheimer's disease · Plasma panel development initiated with a view to focusing on the Oncology market segment · Multiple biomarker discovery and assay development projects delivered · Sales in the period were $708,831 (2009: $807,769), excluding discontinued operations · Funding of $2.4 million received in the period, $1.3 million through share issues and $1.1 million from convertible loans http://investegate.co.uk/Article.aspx?id=201009061352262122S
I don't 'recommend' any 'punt' shares. I don't expect you to understand the terminology of the word 'punt' as that is all you seem to do! As i have never seen you post a bit of research on any board or have any reasoned debate or discussion i can only assume you are a little boy trying to play a mans game. My 4 year old nephew has better grammer and spelling than you... back to school today anyway aren't you so don't expect to see a post before lunch time. FYI i still some in here, i reduced my holding by half a month ago.
It is purely lack of newsflow IMO. I'm happy to sit and wait. mannnan, why don't you run along and follow little bozara, after all you can't make an investment on your own research can you. You muct be back at school today anyway so not alot of time for posting?
Large buyer appears to be out in force again today! 2.5% up currently. News has to be soon! Something for newbies to get thier teeth into: http://archive.wn.com/2010/08/25/1400/turkeyenergy_old1/ GLA
PRLog (Press Release) – Sep 01, 2010 – Rockville, MD, /Marketwire - MarketResearch.com has announced the addition of Espicom Healthcare Intelligence’s new report “Biomarkers: Applications and Trends” to their collection of Biotechnology market reports. For more information, visit http://www.marketresearch.com/product/display.asp?Produc ... While Biomarker research is still in its infancy, great strides have been made in the discovery and utilization of biomarkers in the development of targeted cancer therapeutics and companion diagnostics. Furthermore, there are still significant opportunities in other disease areas to improve productivity by identifying the most suitable developmental candidates earlier during the R&D process. All stakeholders have an important part to play. Regulators across the globe are in the process of establishing the necessary guidelines and framework in which to assess biomarker data. This in turn should encourage the pharma and diagnostic industries to adopt new technologies which will help to transform the drug and diagnostic development process to a “learn and confirm” model. The application of biomarker techniques will shift attrition rates to earlier in the R&D process, enable the reallocation of resources to high probability candidates and help with the development of diagnostics. Numerous companies and service providers are beginning to emerge which can provide the industry with a host of innovative bioinformatic, chemogenomic, genomic, glycoproteomic, metabolomic, peptidomic, pharmacogenomic, proteomic and transcriptomic technology platforms targeting biomarker discovery, development and qualification. Advances in these fields will continue to drive biomarker research forward increasing sample throughput, enhancing levels of detection and leading to the multiplex detection of multiple biomarker panels for use in preclinical research, the clinic and the commercialization of diagnostics. Despite tough economic conditions, innovative companies continue to attract attention from the investment community - a balance between scientific, regulatory and financial resources will be critical for future growth. The biomarker discovery segment is the largest revenue generator and accounted for nearly half of sales in 2009. Biomarkers for use in clinical trials, which currently account for a relatively small segment of sales are forecast to grow significantly by 2015 with a CAGR of 37.6%. Whilst the return on investment is difficult to assess due to the immaturity of the market, key opinion leaders believe biomarkers hold great promise towards the development of a new generation of therapeutics and diagnostics which in the longer term can enhance the personalization of medicine and help to alleviate the burden of healthcare across the globe. http://www.prlog.org/10902445-biomarkers-used-in-clinical-trials-to-grow-38-annually-through-2015.html